Acusphere to Host Conference Call to Discuss Q3 2006 Results

Business Wire, Nov 7, 2006

WATERTOWN, Mass. -- Acusphere, Inc. (NASDAQ: ACUS) announced that it expects to host a conference call on Tuesday, November 14, 2006, at 11:00 AM Eastern Time to discuss the Company's financial results, quarterly highlights and business outlook for its third quarter ended September 30, 2006. The call will include representatives of the Company including Sherri Oberg, President and Chief Executive Officer, John Thero, Senior Vice President and Chief Financial Officer and Dr. Richard Walovitch, Senior Vice President of Clinical Research.

To listen to this conference call via audio webcast, please visit the Investor Relations section of the Company's website (www.acusphere.com) at least ten minutes prior to the start of the call and follow the directions there. The webcast will also be available as a replay, starting approximately one hour after the call is finished, through December 14, 2006. Alternately, to access the call via live telephone, please dial 1-866-202-1971, using confirmation code 41716214. Internationally, the call may be accessed by dialing 1-617-213-8842, using the same confirmation code.

In addition to the webcast replay, a telephone replay will be available on November 14, 2006 through December 14, 2006. To access the replay please call 1-888-286-8010 and use the confirmation code of 70740375. Replay is also available internationally at 1-617-801-6888 using the same confirmation code, 70740375.

About Acusphere, Inc.

Acusphere (NASDAQ: ACUS) is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microparticle technology. Acusphere's three initial product candidates are designed to address large unmet clinical needs within cardiology, oncology and asthma. These product candidates were created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microspheres in a versatile manner that allows particles to be customized to address the delivery needs of a variety of drugs. Acusphere's lead product candidate, Imagify[TM] (perflubutane polymer microspheres) injectable suspension, is a cardiovascular drug in Phase 3 clinical development. Imagify is designed to enable ultrasound to compete more effectively with nuclear stress testing, the leading procedure for detecting coronary heart disease. An estimated 11.9 million procedures are done each year in the U.S. to detect coronary heart disease, the leading cause of death in the United States. For more information about Acusphere visit the Company's web site at www.acusphere.com. "Acusphere" and "Imagify"are trademarks of Acusphere, Inc.